Mangaluru: Dr B Shantharam Baliga feted with ‘Lifetime Achievement Award’

The Ayodhya police booked a senior journalist on Wednesday for raising questions on Uttar Pradesh Chief Minister Yogi Adityanath's visit to the Ram Janmabhoomi for a religious ceremony amid the lockdown over the novel coronavirus pandemic.

The FIR mentions a tweet by Siddharth Varadarajan, editor of news portal 'The Wire', where he said: "On the day the Tablighi Jamaat event was held, Adityanath insisted a large Ram Navami fair planned for Ayodhya from March 25 to April 2 would proceed as usual and that 'Lord Ram would protect devotees from the coronavirus."

Varadarajan had clarified in another tweet that it was "Acharya Paramhans, Hindutva stalwart and head of the official Ayodhya temple trust, who said Ram would protect devotees from coronavirus, and not Adityanath, though he allowed a public event on 25/3 in defiance of the lockdown and took part himself".

Taking the suo-motu cognizance, Faizabad Kotwali police station incharge Nitish Kumar Shrivastava registered an FIR under sections 188 (disobedience to order duly promulgated by public servant) and 505(2) (statements conducing to public mischief) of the Indian Penal Code for doing "disreputable" comment against the chief minister.

Statement by the Founding Editors of The Wire: pic.twitter.com/frw5oRxw18

— The Wire (@thewire_in) April 1, 2020
Reacting to it, Varadarajan termed the FIR "politically motivated, saying that the offences invoked were not even remotely made out.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Bengaluru, Apr 13: Eminent scientist and NITI Aayog member V K Saraswat said on Monday the number of COVID- 19 cases is not going to go beyond what's being reported daily in India as he maintained that the country is in the process of flattening the curve.

The former Scientific Adviser to Defence Minister said the coronavirus positive cases have seen a sharper rise in the last four-five days because of increase in the number of testing.

"It's a good sign; all those asymptomatic cases lying hidden they are also coming out," Saraswat told PTI. "We certainly had a catalytic factor which was basically this (Nizamuddin) Markaz problem which has actually created clusters at different places and that has also been one of the factors for the kind of rise that has taken place."

But he said India is in a much better shape compared to other nations in the battle against COVID-19. "I can only say that the rate is not going to go beyond what has been going on now, may be 700 to 800 cases per day. So, we are in the process of flattening the curve."

The government's decision to declare nation-wide lockdown has paid dividends, Saraswat, a former chief of the Defence Research and Development Organisation, said.

Noting that India has seen a series of virus attacks in the last 15-20 years including Chikungunya and Dengue, he said the emphasis now should be on more and more R & D to find vaccines in advance.